AU772949B2 - Antibodies to human IL-1beta - Google Patents

Antibodies to human IL-1beta Download PDF

Info

Publication number
AU772949B2
AU772949B2 AU33697/01A AU3369701A AU772949B2 AU 772949 B2 AU772949 B2 AU 772949B2 AU 33697/01 A AU33697/01 A AU 33697/01A AU 3369701 A AU3369701 A AU 3369701A AU 772949 B2 AU772949 B2 AU 772949B2
Authority
AU
Australia
Prior art keywords
amino acid
ser
tyr
cdr3
cdr2
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU33697/01A
Other languages
English (en)
Other versions
AU3369701A (en
Inventor
Franco E Di Padova
Hermann Gram
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novartis AG
Original Assignee
Novartis AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=9884137&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AU772949(B2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis AG filed Critical Novartis AG
Publication of AU3369701A publication Critical patent/AU3369701A/en
Application granted granted Critical
Publication of AU772949B2 publication Critical patent/AU772949B2/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • C07K16/245—IL-1
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Pulmonology (AREA)
  • Hematology (AREA)
  • Rheumatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Emergency Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Ophthalmology & Optometry (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Transplantation (AREA)
AU33697/01A 2000-01-21 2001-01-19 Antibodies to human IL-1beta Ceased AU772949B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB0001448 2000-01-21
GBGB0001448.0A GB0001448D0 (en) 2000-01-21 2000-01-21 Organic compounds
PCT/EP2001/000591 WO2001053353A2 (en) 2000-01-21 2001-01-19 Recombinant antibodies to human interkleukin-1 beta

Publications (2)

Publication Number Publication Date
AU3369701A AU3369701A (en) 2001-07-31
AU772949B2 true AU772949B2 (en) 2004-05-13

Family

ID=9884137

Family Applications (1)

Application Number Title Priority Date Filing Date
AU33697/01A Ceased AU772949B2 (en) 2000-01-21 2001-01-19 Antibodies to human IL-1beta

Country Status (33)

Country Link
US (4) US20030124617A1 (enExample)
EP (1) EP1248804B2 (enExample)
JP (2) JP3978338B2 (enExample)
KR (1) KR100697126B1 (enExample)
CN (1) CN1395581B (enExample)
AR (1) AR027253A1 (enExample)
AT (1) ATE346868T1 (enExample)
AU (1) AU772949B2 (enExample)
BR (1) BR0107661A (enExample)
CA (1) CA2396212C (enExample)
CO (1) CO5261584A1 (enExample)
CY (1) CY1107989T1 (enExample)
CZ (1) CZ302738B6 (enExample)
DE (1) DE60124863T3 (enExample)
DK (1) DK1248804T4 (enExample)
ES (1) ES2274865T5 (enExample)
GB (1) GB0001448D0 (enExample)
HK (1) HK1050013A1 (enExample)
HU (1) HUP0204156A3 (enExample)
IL (2) IL150551A0 (enExample)
MX (1) MXPA02007091A (enExample)
MY (1) MY155269A (enExample)
NO (1) NO329816B1 (enExample)
NZ (1) NZ519936A (enExample)
PE (1) PE20011219A1 (enExample)
PL (1) PL207642B1 (enExample)
PT (1) PT1248804E (enExample)
RU (1) RU2264413C2 (enExample)
SI (1) SI1248804T2 (enExample)
SK (1) SK288054B6 (enExample)
TR (1) TR200201780T2 (enExample)
WO (1) WO2001053353A2 (enExample)
ZA (1) ZA200205659B (enExample)

Families Citing this family (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0001448D0 (en) * 2000-01-21 2000-03-08 Novartis Ag Organic compounds
JP4955185B2 (ja) 2000-06-29 2012-06-20 アボット・ラボラトリーズ 二重特異性抗体ならびに作製方法および使用方法
GB0020685D0 (en) 2000-08-22 2000-10-11 Novartis Ag Organic compounds
CA2474616A1 (en) * 2002-01-28 2003-08-07 Medarex, Inc. Human monoclonal antibodies to prostate specific membrane antigen (psma)
GB0303337D0 (en) 2003-02-13 2003-03-19 Celltech R&D Ltd Biological products
ATE491953T1 (de) * 2003-09-15 2011-01-15 Oklahoma Med Res Found Verfahren zur verwendung von cytokintests zur diagnose, behandlung und beurteilung von ankyloider spondylitis
JP4588763B2 (ja) 2004-02-06 2010-12-01 ユニバーシティー オブ マサチューセッツ クロストリジウム・ディフィシル（Ｃｌｏｓｔｒｉｄｉｕｍｄｉｆｆｉｃｉｌｅ）毒素に対する抗体およびその使用
EP1851245B1 (en) 2005-01-26 2012-10-10 Amgen Fremont Inc. Antibodies against interleukin-1 beta
PA8672101A1 (es) * 2005-04-29 2006-12-07 Centocor Inc Anticuerpos anti-il-6, composiciones, métodos y usos
PT1899378E (pt) 2005-06-21 2010-01-26 Xoma Technology Ltd Anticorpos de ligação de il-1β e os seus fragmentos
PL1940465T3 (pl) * 2005-10-26 2013-01-31 Novartis Ag Nowe zastosowanie przeciwciał anty-IL-1beta
EP3219328B1 (en) 2005-12-29 2020-06-17 Janssen Biotech, Inc. Human anti-il-23 antibodies, compositions, method and uses
US7943328B1 (en) 2006-03-03 2011-05-17 Prometheus Laboratories Inc. Method and system for assisting in diagnosing irritable bowel syndrome
EP2021026A1 (en) * 2006-04-14 2009-02-11 Novartis AG Use of il-i antibodies for treating ophthalmic disorders
US20080085524A1 (en) * 2006-08-15 2008-04-10 Prometheus Laboratories Inc. Methods for diagnosing irritable bowel syndrome
US7695718B2 (en) 2006-12-20 2010-04-13 Xoma Technology Ltd. Methods for the treatment of IL-1β related diseases
EP2114443A4 (en) * 2006-12-29 2011-08-10 Abbott Lab IL-1A / IL-1B ANTIBODY WITH DOUBLE SPECIFICITY
AU2008219681A1 (en) 2007-02-28 2008-09-04 Merck Sharp & Dohme Corp. Combination therapy for treatment of immune disorders
KR20160017119A (ko) * 2007-05-29 2016-02-15 노파르티스 아게 항-ｉｌ-1-베타 치료법에 대한 신규 적응증
HRP20141194T1 (hr) * 2007-12-20 2015-04-24 Xoma (Us) Llc Postupci lijeäśenja gihta
CA2727171A1 (en) * 2008-06-06 2009-12-10 Xoma Technology Ltd. Methods for the treatment of rheumatoid arthritis
WO2010028275A1 (en) 2008-09-05 2010-03-11 Xoma Technology Ltd. METHODS FOR TREATING OR PREVENTING IL-1ß RELATED DISEASES
DK2493922T3 (en) 2009-10-26 2017-04-24 Hoffmann La Roche Process for preparing a glycosylated immunoglobulin
EA201201526A1 (ru) 2010-05-07 2013-06-28 Ксома Текнолоджи Лтд. Способы лечения состояний, связанных с il-1b
DE102010033565B4 (de) * 2010-07-27 2012-06-21 Tetec Tissue Engineering Technologies Ag Marker zur Bestimmung von Chondrozyten
IL315833A (en) 2010-08-02 2024-11-01 Regeneron Pharma Mice producing binding proteins containing VL regions
CN103328511B (zh) 2010-09-10 2016-01-20 埃派斯进有限公司 抗-IL-1β抗体及其使用方法
HUE024534T2 (hu) 2011-02-25 2016-01-28 Regeneron Pharma ADAM6 egerek
IL273982B2 (en) 2011-08-05 2023-03-01 Regeneron Pharma Humanized mice possess a universal light chain
DE102011083595A1 (de) 2011-09-28 2013-03-28 Bayer Pharma AG Inhibition der Wirkung von Interleukin 1 beta zur Behandlung der Endometriose
EP2794657B1 (en) 2011-12-19 2017-10-11 Xoma (Us) Llc Methods for treating acne
SG11201403326VA (en) 2011-12-20 2014-07-30 Regeneron Pharma Humanized light chain mice
WO2013122544A2 (en) 2012-02-13 2013-08-22 Agency For Science, Technology And Research IL-1β NEUTRALIZING HUMAN MONOCLONAL ANTIBODIES
PT3597037T (pt) 2012-06-12 2021-06-01 Regeneron Pharma Animais não humanos humanizados com lócus de cadeia pesada de imunoglobulina restrito
BR112016021572A2 (pt) 2014-03-21 2017-10-03 Regeneron Pharma Métodos para preparar um animal não humano geneticamente modificado e para produzir proteínas de ligação, hibridoma, ácido nucleico, célula, e, proteína de ligação
ES2762640T3 (es) 2014-03-21 2020-05-25 Regeneron Pharma Proteínas VL de unión a antígeno que exhiben diferentes características de unión
EP3271403A1 (en) 2015-03-19 2018-01-24 Regeneron Pharmaceuticals, Inc. Non-human animals that select for light chain variable regions that bind antigen
US20190269757A1 (en) 2018-03-05 2019-09-05 Janssen Biotech, Inc. Methods of Treating Crohn's Disease with Anti-IL23 Specific Antibody
CN110818793A (zh) * 2018-08-14 2020-02-21 中山康方生物医药有限公司 抗IL-1β的抗体、其药物组合物及其用途
AU2019383017A1 (en) 2018-11-20 2021-06-03 Janssen Biotech, Inc. Safe and effective method of treating psoriasis with anti-IL-23 specific antibody
KR20220012883A (ko) 2019-05-23 2022-02-04 얀센 바이오테크 인코포레이티드 Il-23 및 tnf 알파에 대한 항체의 병용요법으로 염증성 장질환을 치료하는 방법
BR112022023489A2 (pt) 2020-05-21 2023-03-14 Janssen Biotech Inc Método de tratamento de doença inflamatória intestinal com uma terapia de combinação de anticorpos para il-23 e tnf-alfa

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4772685A (en) 1985-10-02 1988-09-20 Merck & Co., Inc. Immunogenic peptides of human interleukin-1 and the corresponding anti-peptide antibodies
US4935343A (en) * 1986-08-08 1990-06-19 Syntex (U.S.A.) Inc. Monoclonal antibodies for interleukin-1β
FR2640146B1 (fr) * 1988-12-08 1993-12-24 Commissariat A Energie Atomique Anticorps monoclonaux anti-interleukines 1(alpha) et 1(beta), leur procede de production et applications desdits anticorps a la detection des interleukines 1(alpha) et 1(beta) et en therapeutique
GB8928874D0 (en) 1989-12-21 1990-02-28 Celltech Ltd Humanised antibodies
US5859205A (en) * 1989-12-21 1999-01-12 Celltech Limited Humanised antibodies
GB9014932D0 (en) 1990-07-05 1990-08-22 Celltech Ltd Recombinant dna product and method
JP3714683B2 (ja) * 1992-07-30 2005-11-09 生化学工業株式会社 抗リウマチ剤
US5429614A (en) 1993-06-30 1995-07-04 Baxter International Inc. Drug delivery system
WO1995001997A1 (en) * 1993-07-09 1995-01-19 Smithkline Beecham Corporation RECOMBINANT AND HUMANIZED IL-1β ANTIBODIES FOR TREATMENT OF IL-1 MEDIATED INFLAMMATORY DISORDERS IN MAN
US6051228A (en) 1998-02-19 2000-04-18 Bristol-Myers Squibb Co. Antibodies against human CD40
GB0001448D0 (en) * 2000-01-21 2000-03-08 Novartis Ag Organic compounds

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
REITER ET AL. 1999 JMB VOL. 290, PP 685-698 *

Also Published As

Publication number Publication date
EP1248804B1 (en) 2006-11-29
CA2396212A1 (en) 2001-07-26
HUP0204156A2 (hu) 2003-03-28
WO2001053353A3 (en) 2002-04-04
MXPA02007091A (es) 2002-12-13
MY155269A (en) 2015-09-30
US20090232803A1 (en) 2009-09-17
CZ302738B6 (cs) 2011-10-12
DE60124863D1 (de) 2007-01-11
HK1050013A1 (zh) 2003-06-06
KR20020073178A (ko) 2002-09-19
NZ519936A (en) 2004-02-27
SI1248804T2 (sl) 2010-04-30
PT1248804E (pt) 2007-02-28
ES2274865T3 (es) 2007-06-01
GB0001448D0 (en) 2000-03-08
BR0107661A (pt) 2002-11-19
CA2396212C (en) 2013-04-02
ATE346868T1 (de) 2006-12-15
JP3978338B2 (ja) 2007-09-19
NO20023266L (no) 2002-08-28
PL207642B1 (pl) 2011-01-31
ZA200205659B (en) 2003-12-31
AU3369701A (en) 2001-07-31
KR100697126B1 (ko) 2007-03-20
TR200201780T2 (tr) 2003-01-21
IL150551A0 (en) 2003-02-12
CN1395581B (zh) 2010-10-13
IL150551A (en) 2010-11-30
RU2002121649A (ru) 2004-03-10
PE20011219A1 (es) 2001-12-17
NO329816B1 (no) 2010-12-27
NO20023266D0 (no) 2002-07-05
AR027253A1 (es) 2003-03-19
SI1248804T1 (sl) 2007-06-30
CY1107989T1 (el) 2013-09-04
CN1395581A (zh) 2003-02-05
WO2001053353A2 (en) 2001-07-26
SK288054B6 (sk) 2013-03-01
EP1248804A2 (en) 2002-10-16
CO5261584A1 (es) 2003-03-31
JP2007097598A (ja) 2007-04-19
EP1248804B2 (en) 2009-12-02
CZ20022531A3 (cs) 2002-10-16
SK10352002A3 (sk) 2003-03-04
PL356297A1 (en) 2004-06-28
US20060251660A1 (en) 2006-11-09
JP2003520595A (ja) 2003-07-08
DK1248804T4 (da) 2010-04-06
DE60124863T2 (de) 2007-04-26
US20110182894A1 (en) 2011-07-28
RU2264413C2 (ru) 2005-11-20
US7491392B2 (en) 2009-02-17
ES2274865T5 (es) 2010-04-19
DK1248804T3 (da) 2007-02-26
US20030124617A1 (en) 2003-07-03
DE60124863T3 (de) 2010-05-20
HUP0204156A3 (en) 2005-09-28

Similar Documents

Publication Publication Date Title
AU772949B2 (en) Antibodies to human IL-1beta
AU2001295490B2 (en) Antibodies to human IL-1beta
AU2001295490A1 (en) Antibodies to human IL-1beta

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)